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Abstract 
Types of cutaneous lymphoma (CL) and their incidences may vary among geographic areas or ethnic groups. 
The present study aimed to investigate the incidences of various CLs in Japan, using epidemiological data 
from a nationwide registration system for CLs. Between 2007 and 2011, 1,733 new patients with CL were 
registered from over 600 dermatological institutes in Japan. The 1,733 patients registered included 1,485 
(85.7%) patients with mature T- and NK-cell neoplasms, 224 (12.9%) with B-cell neoplasms and 24 (1.4%) 
with blastic plasmacytoid dendritic cell neoplasm. Mycosis fungoides (MF) is the most common CL subtype 
in the present study (750 patients, 43.3%). The proportion of MF patients with early-stage disease was 73%, 
similar to that of previous studies from other cohorts. The incidence rates of adult T-cell 
leukemia/lymphoma and extranodal NK/T cell lymphoma, nasal type were 16.7% and 2.0%, respectively, 
which may account for the higher incidence of mature T- and NK-cell neoplasms in Japan, as compared 
with that in the United States and Europe. A male predominance was observed in most types of CLs, except 
for several CL subtypes such as subcutaneous panniculitis-like T-cell lymphoma.  
 
Key words: adult T-cell leukemia/lymphoma, cutaneous lymphoma, extranodal NK/T cell lymphoma, nasal type, Mycosis 
fungoides, subcutaneous panniculitis-like T-cell lymphoma. 
      
 3
 
Introduction 
Cutaneous lymphomas (CLs) are the second-most common type of extranodal non-Hodgkin’s lymphoma, 
after gastrointestinal lymphomas.1 CLs are defined as lymphomas with skin infiltration of neoplastic 
lymphocytic cells, without nodal or internal involvement at diagnosis. The WHO classification for tumors of 
hematologic and lymphoid tissue, including CLs, was published in 2008, through several consensus 
meetings, and is based on a combination of clinicopathological, phenotypic, genetic and molecular 
characteristics.2 Mycosis fungoides (MF) is the most common type of CL. In 2007, a revised version of the 
mycosis fungoides/ Sézary syndrome (MF/SS) staging system was published; thereafter, a TNM 
classification system was proposed for CLs other than MF/SS. 3, 4 Using the new criteria, clinical outcomes 
including survival data have recently been reported from the United Kingdom and Japan.5, 6 However, these 
studies analyzed clinical data from only a single medical center over 25- or 30-year periods.  
CL is a rare disease entity, and is difficult to study on a large scale. Thus, most epidemiological surveys on 
CLs have been limited to case series reports, mainly of single medical centers.7-12 Epidemiologic data of 
CLs has not been fully evaluated to date. Entry of data into a comprehensive registry of CLs is required in 
many parts of the world. To date, a few large-scale epidemiologic studies on CLs have been performed 
mainly in the United States and Europe.13-15 The findings from the present study, including the incidence 
rates of CLs, may be somewhat different from those studies. Indeed, the incidence pattern of CLs has been 
reported to be different by country or ethnic group, like that of gross lymphoproliferative disorders. For 
example, adult T-cell leukemia/lymphoma (ATLL) is endemic in southwest Japan, especially on Kyushu 
Island.16, 17 However, it is very rare in the United States and Europe.13-15 
In 2007, we established a nationwide registry system for Japanese CLs, in cooperation with the Japanese 
Skin Cancer Society (JSCS) Lymphoma Study Group. The present registry covers the whole country, and is 
aimed at elucidating the distinct pattern of Japanese CLs, mainly using the WHO classification and the 
revised version of MF/SS clinical staging.2, 3 In addition, the present registry can minimize the kind of 
selection bias resulting from single-center analysis because data from hundreds of institutions throughout 
Japan are included. Such analyses will be conducted over the whole area of Japan each year. Thus, this 
registry will facilitate further clinical study and basic research in the near future. 
 
Methods 
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We analyzed the incidence pattern of CLs from 2007 to 2011. The present registry covers the entire nation 
and includes more than 600 dermatological institutes throughout Japan, all of which have been approved as 
residency programs for board-certified dermatologists by the Japanese Dermatological Association (JDA) 
(Table 1). On average, a total of 628 institutes per year participated in the present study. In addition, the 
total number of the registered institutes of each prefecture is shown in Table 1. The diagnosis of CL was 
confirmed according to the WHO classification mentioned above.2 Subjects were newly diagnosed patients 
with CLs in each institute. Clinical data including age at diagnosis, sex, TNM classification, clinical stage, 
anatomic site of the primary lesion, nodal or extracutaneous involvement, and initial therapy were retrieved 
from the medical database of each medical institute. In the present study, unconventional sites such as groin 
were excluded from the statistical analyses, because of its small number. Those data were submitted 
electronically without personal information to our data center once a year. This study was approved by the 
ethics board committee (the review board of JDA). 
The comprehensive classification of CL and hematopoietic neoplasms with marked affinity for the skin 
was presented by the European Organization for Research and Treatment of Cancer (EORTC) in 2005.13 
This framework of CL classification was essentially duplicated by the WHO classification, with several 
nominal or hierarchical differences.2 The present registry has dealt with CLs, shown in Table 2. Clinical 
stage and TNM classification of patients with MF/SS were identified using the International Society for 
Cutaneous Lymphomas (ISCL)/EORTC proposal in 2007 (which was modified in 2011).3, 18  
 
Results 
In total, 1,733 patients with CLs have been registered between 2007 and 2011 (Table 2). The patients ranged 
from 1 to 100 years (median, 65) in age, and included 978 males and 751 females (M: F ratio 1.30). Mature 
T-cell and NK-cell neoplasm was the most common type of CLs, accounting for 1,485 (85.7%) patients. 
Next in prevalence, 224 (12.9%) of 1,733 patients had mature B-cell neoplasm. The remaining 24 (1.4%) 
patients had blastic plasmacytoid dendritic cell neoplasm (BPDN).  
MF was the most common subtype of mature T-cell and NK-cell neoplasms, comprising 50.5% of cases, 
followed by ATLL (290 patients; 19.5%), primary cutaneous CD30+ T-cell lymphoproliferative disorders 
(208 patients; 14.0%), and peripheral T-cell lymphoma, not otherwise specified (NOS) (100 patients; 6.7%). 
Other subtypes of mature T-cell and NK-cell neoplasms included 34 (2.3%) subcutaneous panniculitis-like 
T-cell lymphoma (SPTCL), 34 (2.3%) extranodal NK/T-cell lymphoma, nasal type (ENKL), and 33 (2.2%) 
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SS cases. The incidences of rare disease entities including primary cutaneous CD4+ small/medium T-cell 
lymphoma, primary cutaneous γδ T-cell lymphoma and primary cutaneous CD8+ aggressive epidermotropic 
cytotoxic T-cell lymphoma were 25 (1.7%), 5 (0.3%) and 6 (0.4%), respectively. 
The most common mature B-cell neoplasm subtype was primary cutaneous diffuse large-cell lymphoma, 
leg type (95 patients; 42.4%), followed by extranodal marginal zone lymphoma of mucosa-associated 
lymphoid tissue (MALT) (72 patients; 32.1%), primary cutaneous follicle center lymphoma (pcFCL) (37 
patients; 16.5%), and IVLBCL (20 patients; 8.9%). 
 A male predominance was observed in all CLs (M: F ratio 1.30), with over 2-fold male predominance for 
BPDN (M: F ratio 5.00), SS (M: F ratio 3.71), IVLBCL (M: F ratio 2.33), and pcFCL (M: F ratio 2.08). In 
contrast, a female predominance was observed in SPTCL (M: F ratio 0.55), followed by in ENKL (M: F 
ratio 0.62), primary cutaneous CD4+ small/medium T-cell lymphoma (M: F ratio 0.79) and lymphomatoid 
papulosis (LyP) (M: F ratio 0.83). 
 The median age at diagnosis was low in patients with LyP (53.5 years) and SPTCL (55 years), as compared 
with that of all CLs (65 years). In contrast, the median age at diagnosis was high in patients with BPDN 
(77.5 years) and pcDLBCL, leg type (77 years). In general, the patient’s age was high in mature B-cell 
neoplasm, as compared with those in mature T-cell and NK-cell neoplasm (median ages of 70 and 64 years, 
respectively).  In reference to age distribution, bimodal distributions of age at diagnosis were found in LyP 
(the fourth and the sixth decades) and SPTCL (the fifth and the seventh decades). 
 
Clinical stage of mycosis fungoides/ Sézary syndrome (Table 4) 
In terms of clinical staging, the 744 MF⁄SS patients included 229 (29.6%) with stage IA, 303 (39.1%) with 
stage IB, 33 (4.3%) with stage IIA, 86 (11.1%) with stage IIB, 57 (7.4%) with stage IIIA, 7 (0.9%) with 
stage IIIB, 17 (2.2%) with stage IVA1, 28 (3.6%) with stage IVA2 and 14 (1.8%) with stage IVB. In all, 565 
patients (73%) had early-stage disease (stage I + IIA). The remaining 209 (27%) patients had the 
advanced-stage disease (stage IIB + III + IV). A male predominance was observed in stage IIIA (M: F ratio 
4.18), stage IIIB (M: F ratio 2.50) and stage IVA1 (M: F ratio 2.40). In contrast, a female predominance was 
observed in stage IVA2 (M: F ratio 0.75). The median ages at diagnosis were 61 to 62 years in stage IA to 
IIB and stage IIIB, and 64 to 70 years in stage IIIA and IV.  
 
Anatomic site of the primary skin lesion (Figure 1A-G) 
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The skin lesion sites of primary cutaneous anaplastic large cell lymphoma were distributed just about evenly. 
The most commonly affected sites were the lower extremities in SPTCL (62%) and the head/neck or the 
trunk in primary cutaneous CD4+ small/medium T-cell lymphoma (52%). In pcFCL and MALT, the head 
and neck were commonly affected (84% and 56%, respectively). In contrast, the lower extremities were the 
most commonly affected sites in DLBCL, leg type (45%). BPDN preferentially arose on the trunk (83%). 
 
Discussion 
In the present study, we aimed to reveal the distinct characteristics of the Japanese pattern of CL. After the 
initiation of the annual registry in 2007, 1,733 newly diagnosed patients with CLs have been registered from 
over 600 dermatological institutes through Japan. The present registry is not a ‘population-based’ study in a 
precise sense. However, the data presented herein are believed to be representative of the Japanese CLs. A 
possible limitation of the study includes uncertainty about the accuracy of the diagnostic procedure in each 
institute with lack of central pathology review. However, we believe this may not be a matter of great 
importance, because all enrolled institutes have residency programs for dermatologists to become 
board-certified by JDA. By the present registry system, trends of overall incidence and disease distribution 
of CLs in Japan will be evaluated continually. 
 We showed that the majority (85.7%) of CL cases was mature T-cell and NK-cell neoplasm, more or less 
similar to findings in previous studies from Japan and elsewhere.7-15 However, in detail, the incidence rate of 
mature T-cell and NK-cell neoplasm in the present study was 8.7 to 14.4% higher than in those of the 
United States and Europe. In contrast, the incidence of mature B-cell neoplasm (12.9%) was much lower: 
10.1 to 15.6% lower than in the west (Table 3). It is noteworthy that the incidence rate of MALT in the 
present study was lower than in those of the United States and Europe. Occasionally, the distinction between 
B-cell pseudolymphoma and MALT can be very difficult in some patients.19 Thus, one of possible causes 
may include the diagnostic difficulty of MALT. The overall incidence pattern of CLs in the present study 
was similar to that in previous studies from single centers of Japan and Korea (Table 3).8, 12 As compared 
with the incidence of CLs in other countries or regions, MF/SS occurred at a similar frequency (45.2%) in 
Japan, while the incidence rates of ATLL and ENKL were observed to be 16.7% and 2.3%, respectively. 
The incidence rate of ENKL was higher than those of the United States and Europe, and lower than those of 
Korea and Taiwan.11, 12, 20 
 ATLL is a distinct hematological neoplasm caused by the human T-cell lymphotropic virus type I 
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(HTLV-1) - infected malignant CD4 positive T cells.21-23 The endemic areas of ATLL include 
high-prevalence regions of HTLV-1, such as southwest Japan, various Caribbean countries, South America, 
and Central Africa.24-27 ATLL shows various clinical and prognostic features, and is classified into four 
categories according to the Shimoyama classification: acute, lymphoma, chronic, and smoldering subtypes.28 
Cutaneous lesions are frequently observed in patients with ATLL, accounting for more than 50%.21,29 
Moreover, many types of ATLL-associated eruption have been reported to date.30-32 The present study 
showed high prevalence of ATLL in Japan compared with other countries or regions including Korea (Table 
3). 
ENKL is characterized by pleomorphic cell infiltration with NK-cell phenotype, which ordinarily 
demonstrates positivity to Epstein-Barr virus -encoded early small RNA by in-situ hybridization.2 Typically, 
pathological features include vascular damage and tissue necrosis by angiocentric infiltration of tumor cells. 
Frequently, ENKL affects the upper aerodigestive tract, followed by skin, soft tissue, the gastrointestinal 
tract and testes.2 It is more prevalent in East Asia, Central America and South America than in Europe and 
the United States.13, 33-35 Also, the incidence of ENKL in CLs was reported to be significantly higher in 
Korea (15% and 20.7%) than in Europe and the United States.12, 20 In three single-institution studies from 
Japan, the incidence rate of ENKL has ranged from 3.8% to 8.8%.8, 36, 37 In the present study, the incidence 
was somewhat lower (2.3%) than these previous studies. The difference may reflect the kind of selection 
bias specific to single-institution studies. Our results suggest that the high incidence rates of mature T-cell 
and NK-cell neoplasm are associated with the prevalence of ATLL in Japan, unlike that of ENKL in Korea. 
MF is the most common CL subtype in the present study as well as in almost all counties or ethnicities. In 
the past, staging of MF/SS was performed according to the previously proposed staging system.38, 39 Prior to 
the establishment of the new staging system, several clinical studies had been conducted on relatively large 
cohorts of CTCL for such a rare disease entity.40-42 In 2007, the revised staging system for MF/SS was 
released by the ISCL/EORTC (which was in turn modified in 2011).3, 18 This system adopted a newly 
proposed classification of tumor-node-metastasis-blood (TNMB) rating. Since then, two clinical studies of 
MF/SS have been conducted in the United Kingdom and Japan.5, 6 In the present study, the proportion of 
patients with early-stage (IA to IIA) was 73%, similar to that of the previous studies (70.7% and 78%) 
(Table 5). Stage IB accounted for 39.1% of the total MF/SS in the present study, making it the most 
prevalent clinical stage. This finding is similar to the results of previous studies (38.8% and 38%) (Table 
5) .5, 6 In addition, a predominance of males among MF/SS patients was shown in the present study, as in 
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previous reports.5, 6, 8, 9, 12-15, 20, 40-42 Notably, a male predominance was observed in erythrodermic MF or SS, 
with over 2-fold male predominance for stage IIIA (M: F ratio 4.18), stage IIIB (M: F ratio 2.50), and stage 
IVA1 (M: F ratio 2.40). 
 We evaluated the distinct anatomical distributions of the skin lesions in patients with several types of CLs. 
In patients with pcFCL and MALT, the head and neck were the most commonly affected sites, as in 
previous reports from the United States and Asia.15, 43 By contrast, in Europe, the trunk was the most 
commonly affected site of pcFCL and MALT.44-46 These results suggest that a difference in preferentially 
affected anatomic site in patients with pcFCL and MALT may exist, at least between Europe and the United 
States/Asia. By definition, the lower extremities are the most common site in patients with pcDLBCL, leg 
type. Primary cutaneous small/medium CD4+ T-cell lymphoma is a rare CL entity with an indolent clinical 
course, which has been shown to preferentially affect the head and neck.13, 47, 48 In the present study, the 
trunk in addition to the head and neck was the most common site of primary cutaneous small/medium CD4+ 
T-cell lymphoma. SPTCL is a distinct CL entity, characterized by primarily subcutaneous (mainly fat tissue) 
infiltration of malignant T lymphocytes with cytotoxic molecules. It predominantly affects the legs.13, 49 
Also, we found that the lower extremities were the most commonly affected site in SPTCL (62%). In 
addition, a female predominance was demonstrated in Japan, as in a previous report.49  
 The present study was conducted to investigate the nationwide incidence patterns of Japanese CL patients, 
according to the WHO classification. It provides important data about trends in the overall incidence pattern 
of Japanese CLs. In particular, the high prevalences of ATLL and ENKL in Japan are shown, with 
considerable accuracy. A male predominance was observed in most types of CLs, except for SPTCL, ENKL, 
primary cutaneous CD4+ small/medium T-cell lymphoma and LyP. The present study showed that the 
proportion of patients in each clinical stage of MF/SS was similar to that in previous studies. In the future, 
accumulated data from the present registry will allow us to investigate the etiology of varying CL subtypes, 
and to conduct targeted clinical research based on the characteristics of CLs in Japan.  
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LEGENDS FOR FIGURE 
Figure 1. Anatomic distribution. (A-G) The anatomic sites of the primary skin lesion are shown in the graphic representation: 
(A) Primary cutaneous anaplastic large cell lymphoma (pcALCL), (B) Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), 
(C) Primary cutaneous CD4+ small/medium T-cell lymphoma, (D) Primary cutaneous follicle center lymphoma (pcFCL), (E) 
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), (F) Primary cutaneous diffuse large-cell 
lymphoma, leg type (pcDLBCL, leg type), and (G) Blastic plasmacytoid dendritic cell neoplasm (BPDN). 
 
